- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04518982
Sintilimab and Lenalidomide as a Treatment for CAEBV
August 16, 2020 updated by: Zhao Wang
Sintilimab and Lenalidomide as a Treatment for CAEBV:a Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial
This study is a multi-center, prospective, randomized, controlled clinical study to evaluate the effectiveness of a combination regimen of Sintilimab and lenalidomide in patients with chronic active EBV infection.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
51
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Beijing, China
- Recruiting
- Beijing Friendship Hospital, Capital Medical University
-
Contact:
- jingshi wang
- Phone Number: 86-010-63139862
- Email: wangjingshi987@126.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with CAEBV confirmed by WHO criteria.
- The Eastern United States Oncology Cooperative group (ECOG) Physical Status score is 0 or 1.
- Before the study, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3× normal upper limit (ULN); Total bilirubin ≤2 times the normal upper limit; Serum creatinine ≤1.5 times the normal value.
- Absolute neutrophil count ≥1×109/L; Platelet ≥50×109/L; Hemoglobin ≥60 g/L.
- International standardized ratio ≤2.0, prothrombin time ≤1.5×ULN.
- A woman of childbearing age must be determined not to be pregnant by a pregnancy test and is willing to take effective measures to prevent pregnancy during the trial period and ≥12 months after the last administration of the drug; All male subjects used contraceptive methods during the study period and ≥6 months after the last administration;
- Sign the informed consent.
Exclusion Criteria:
- There is evidence that EBV is associated with hematologic disease or malignancy, such as hemophagocytic syndrome, lymphoma-like granulomatosis, post-transplant lymphoproliferative disease, non-Hodgkin's lymphoma, Burkitt lymphoma, nasopharyngeal cancer, and gastric cancer.
- Symptomatic EBV-associated diseases of the major organs, including the central nervous system and lungs.
- Abnormal thyroid function.
- Patients with grade II or above heart disease (including grade II) were identified according to the New York Heart Association (NYHA) score.
- Have received any of the following treatments: PD-1 antibody, PD-L1 antibody or lenalidomide; Received any research drug within 12 weeks prior to the first use of the study drug; Another clinical study was also included.
- Other primary malignancies occur within 5 years before the first administration of the drug, except those that are locally curable after radical treatment (such as basal or squamous cell skin cancer, superficial bladder cancer or carcinoma of the prostate, cervix or breast in situ, etc.).
- A history of organ transplantation (such as liver transplantation, kidney transplantation, etc.).
- Hematopoietic stem cell transplantation is expected during the study period.
- Active hepatitis B (defined as hepatitis B surface antigen [HBsAg] positive during screening, or hepatitis B virus DNA titer test in peripheral blood greater than 1×103 copies/ml), and active hepatitis C (defined as hepatitis C antibody [HCV-AB] and HCV-RNA positive during screening). Serum HIV antigen or antibody positive. A history of syphilis.
- Had major surgery within 4 weeks prior to the first medication or was expected to require major surgery during the study period.
- Pregnant and lactating women;
- A history of serious mental illness or drug abuse;
- Uncontrollable infections (including lung infections, intestinal infections, etc.); Internal organ active massive hemorrhage (including gastrointestinal hemorrhage, alveolar hemorrhage, intracranial hemorrhage, etc.);
- Allergic to the test drug ingredients or to a more severe allergic constitution;
- Patients who cannot comply during the trial and/or follow-up phase.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: The control group
|
Drug: Sintilimab placebo ivgtt on day 1.
Drug: lenalidomide placebo orally once a day, day 1-14.
|
Experimental: The experimental group
|
Drug: Sintilimab 200mg ivgtt on day 1.
Drug: lenalidomide 10mg orally once a day, day 1-14.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response rate
Time Frame: Twelve weeks after treatment
|
The rate of decline in ebV-DNA copy (defined as a 2log decrease in EBV-DNA copy) or negative rate in peripheral blood mononuclear cells and plasma
|
Twelve weeks after treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Spleen size
Time Frame: Twelve weeks after treatment
|
Twelve weeks after treatment
|
|
T and B lymphocyte subsets
Time Frame: Twelve weeks after treatment
|
Twelve weeks after treatment
|
|
Pathological tissue or bone marrow
Time Frame: Twelve weeks after treatment
|
Twelve weeks after treatment
|
|
treatment-related adverse events as assessed by CTCAE v4.0
Time Frame: through study completion, an average of 1 years
|
Adverse events including thyroid function, liver function damage, myelosuppression, infection, bleeding and so on.
|
through study completion, an average of 1 years
|
survival
Time Frame: 1 year
|
From enrollment until death or the end of the experiment
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 1, 2020
Primary Completion (Anticipated)
August 1, 2021
Study Completion (Anticipated)
August 1, 2021
Study Registration Dates
First Submitted
August 16, 2020
First Submitted That Met QC Criteria
August 16, 2020
First Posted (Actual)
August 19, 2020
Study Record Updates
Last Update Posted (Actual)
August 19, 2020
Last Update Submitted That Met QC Criteria
August 16, 2020
Last Verified
August 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Sintilimab,Lenalidomide,CAEBV
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on CAEBV
-
Beijing Friendship HospitalNot yet recruiting
-
Beijing Friendship HospitalEnrolling by invitation
Clinical Trials on Sintilimab and lenalidomide
-
Beijing Tiantan HospitalRecruiting
-
RemeGen Co., Ltd.Recruiting
-
Innovent Biologics (Suzhou) Co. Ltd.Innovent Biologics (USA), Inc.WithdrawnMetastatic Cutaneous Melanoma | Unresectable Cutaneous MelanomaUnited States, Germany, France, Australia, Spain, Switzerland, United Kingdom
-
Innovent Biologics (Suzhou) Co. Ltd.CompletedAdvanced or Metastatic NSCLCChina
-
Innovent Biologics (Suzhou) Co. Ltd.Recruiting
-
RenJi HospitalNot yet recruitingThird-line Treatment | Dvanced Duodenal Adenocarcinoma | Furquinelone Combined With Sintilimab
-
Innovent Biologics (Suzhou) Co. Ltd.Completed
-
Zhejiang Cancer HospitalNot yet recruitingEsophageal Cancer | Elderly Patients | Immunotherapy | Sintilimab | Chemoradiotherapy
-
Zhejiang Cancer HospitalRecruitingEsophageal Squamous Cell CarcinomaChina
-
Peking Union Medical College HospitalRecruiting